Evidence map›Paper›PMID 27472081›Full record

ArticleInvestigative ophthalmology & visual science2016

Prevention of Proliferative Vitreoretinopathy by Suppression of Phosphatidylinositol 5-Phosphate 4-Kinases.

Gaoen Ma, Yajian Duan, Xionggao Huang, Cynthia X Qian, Yewlin Chee, Shizuo Mukai, Jing Cui, Arif Samad, Joanne Aiko Matsubara, Andrius Kazlauskas and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Proliferative Vitreoretinopathy: A Reappraisal.Journal of clinical medicine · 2023
    Review
  3. Article
  4. Development of potent and selective degraders of PI5P4Kγ.European journal of medicinal chemistry · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Gaoen MaSchepens Eye Research Institute, Boston, Massachusetts, United States 2Massachusetts Eye and Ear, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States 4Aier School of Ophthalmology.
Yajian DuanSchepens Eye Research Institute, Boston, Massachusetts, United States 2Massachusetts Eye and Ear, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Xionggao HuangSchepens Eye Research Institute, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Cynthia X QianMassachusetts Eye and Ear, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Yewlin CheeMassachusetts Eye and Ear, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Shizuo MukaiMassachusetts Eye and Ear, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Jing CuiThe University of British Columbia, Vancouver, British Columbia, Canada.
Arif SamadDalhousie University, Halifax, Nova Scotia, Canada.
Joanne Aiko MatsubaraThe University of British Columbia, Vancouver, British Columbia, Canada.
Andrius KazlauskasSchepens Eye Research Institute, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Patricia A D'AmoreSchepens Eye Research Institute, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Shuyan GuAier School of Ophthalmology, Central South University, Changsha, Changsha Province, China.
Hetian LeiSchepens Eye Research Institute, Boston, Massachusetts, United States 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Massachusetts Eye and Ear Infirmary · USHarvard University · USSmith-Kettlewell Eye Research Institute · USUniversity of British Columbia · CACentral South University · CNDalhousie University · CA

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
PDGF and PVRR01EY012509 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI LEI, HETIAN · 2000 to 2017
$8.5M
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY012509
6 · The paper itself

Abstract

purposePrevious studies have shown that vitreous stimulates degradation of the tumor suppressor protein p53 and that knockdown of phosphatidylinositol 5-phosphate 4-kinases (PI5P4Kα and -β) abrogates proliferation of p53-deficient cells. The purpose of this study was to determine whether vitreous stimulated expression of PI5P4Kα and -β and whether suppression of PI5P4Kα and -β would inhibit vitreous-induced cellular responses and experimental proliferative vitreoretinopathy (PVR).

methodsPI5P4Kα and -β encoded by PIP4K2A and 2B, respectively, in human ARPE-19 cells were knocked down by stably expressing short hairpin (sh)RNA directed at human PIP4K2A and -2B. In addition, we rescued expression of PI5P4Kα and -β by re-expressing mouse PIP4K2A and -2B in the PI5P4Kα and -β knocked-down ARPE-19 cells. Expression of PI5P4Kα and -β was determined by Western blot and immunofluorescence. The following cellular responses were monitored: cell proliferation, survival, migration, and contraction. Moreover, the cell potential of inducing PVR was examined in a rabbit model of PVR effected by intravitreal cell injection.

resultsWe found that vitreous enhanced expression of PI5P4Kα and -β in RPE cells and that knocking down PI5P4Kα and -β abrogated vitreous-stimulated cell proliferation, survival, migration, and contraction. Re-expression of mouse PIP4Kα and -β in the human PI5P4Kα and -β knocked-down cells recovered the loss of vitreous-induced cell contraction. Importantly, suppression of PI5P4Kα and -β abrogated the pathogenesis of PVR induced by intravitreal cell injection in rabbits. Moreover, we revealed that expression of PI5P4Kα and -β was abundant in epiretinal membranes from PVR grade C patients.

conclusionsThe findings from this study indicate that PI5P4Kα and -β could be novel therapeutic targets for the treatment of PVR.

Indexed as

AnimalsCell MovementCell ProliferationCells, CulturedCell SurvivalGene Knockdown TechniquesHumansMiceMice, KnockoutPhosphotransferases (Alcohol Group Acceptor)RabbitsRetinal DetachmentVitreoretinopathy, ProliferativeVitreous BodyPhosphotransferases (Alcohol Group Acceptor)PI5P4Kbeta protein, mousePIP4K2A protein, human

Identifiers

PMID27472081
PMCPMC4974024
OpenAlexW2494688951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.